Severe asthma (with high neutrophils), autoimmune diseases, i.e. rheumatoid arthritis, systemic sclerosis, and chronic kidney disease-induced cardiovascular complications
Severe asthma (with high neutrophils), autoimmune diseases, i.e. rheumatoid arthritis, systemic sclerosis, and chronic kidney disease-induced cardiovascular complications
FB704A can neutralize IL-6 specifically and inhibit IL-6/IL-6R classic- and trans-signaling simultaneously, thereby treating and preventing immune-related diseases.
Research Code | Therapeutic Area | Indication | Pre-Clinical | Phase I | Phase II | Phase III | NDA | Market | More |
---|
FB704A is an innovative monoclonal antibody drug that neutralizes IL-6. By inhibiting both the classical and trans-signaling pathways of IL-6, it explores the improvement of symptoms in severe neutrophilic asthma.
建議您使用以下瀏覽器觀看合一網站,
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?